CLSA PREMIUM (06877) profit before tax for the first quarter was approximately HK$1.8 million, up more than 150% year over year
According to the Zhitong Finance App, CLSA PREMIUM (06877) issued an announcement. According to the Group's unaudited comprehensive management accounts for the 3 months ended March 31, 2024, unaudited revenue exceeded HK$20 million, mainly from product sales through the company's B2B and B2C distribution channels. For the three months ended March 31, 2024, unaudited profit before tax was approximately HK$1.8 million, an increase of more than 150% compared with the unaudited profit before tax of HK$700,000 for the three months ended March 31, 2023. Furthermore, compared to the first quarter of 2023
CLSA PREMIUM: 2023 ANNUAL REPORT
CLSA PREMIUM (06877.HK): Ma Anyang appointed as independent non-executive director
Gelonghui, March 20 | CLSA PREMIUM (06877.HK) announced that: (a) Ma Xufei has proposed the resignation of the company's independent non-executive director, chairman of the company's remuneration committee, and member of the company's audit committee, corporate governance committee and nomination committee due to the need to invest more energy in other business arrangements; (b) Ma Anyang has been appointed as the company's independent non-executive director, chairman of the company's remuneration committee, and each member of the company's audit committee, corporate governance committee and nomination committee.
CLSA PREMIUM (06877) announced annual results, with an annual profit of HK$9.842 million, turning a year-on-year loss into a profit
CLSA PREMIUM (06877) released Audited for the year ended December 31, 2023...
CLSA PREMIUM: AUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Ministry of Finance: The total profit of state-owned enterprises in 2023 was 4633.28 billion yuan, up 7.4% year-on-year
From January to December, the main efficiency indicators of state-owned and state-owned enterprises across the country continued to grow steadily, and the upward trend was further consolidated.
CLSA Premium to Return to Profit
CLSA Premium (HKG:6877) expects a consolidated net profit of almost HK$7.7 million for the year through December 2023, as against a loss of about HK$31.1 million in the preceding year. The forex trade
CLSA PREMIUM (06877) is expected to achieve annual net profit of approximately HK$7.7 million, turning a year-on-year loss into profit
According to Zhitong Finance App, CLSA PREMIUM (06877) issued an announcement. The board of directors of the company expects the Group to obtain a consolidated net profit of about HK$7.7 million for the year ended 31 December 2023, and an audited net loss of about HK$31.1 million for the year ended 31 December 2022. The expected net profit is mainly due to a significant increase in the healthcare business in 2023, and the revenue from sales of health products more than tripled the 2022 revenue. Furthermore, trading continues to be suspended.
CLSA PREMIUM: POSITIVE PROFIT ALERT AND QUARTERLY UPDATE ON PROGRESS OF RESUMPTION
CLSA PREMIUM: 2023 Interim Report
CLSA Premium Swings to Profit in H1
CLSA Premium (HKG:6877) recorded a profit attributable to shareholders of HK$5.6 million for the first half, swinging from the loss of HK$17.5 million a year earlier. Earnings per share stood at HK$0.
CLSA PREMIUM: UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
CLSA PREMIUM (06877.HK) will hold a board meeting on August 14 to approve interim results
On July 28, 丨CLSA PREMIUM (06877.HK) announced that a board meeting will be held on August 14, 2023 to approve the company and its subsidiaries' interim results and announcements for the six months ended June 30, 2023, and consider the payment of interim dividends (if any).
CLSA PREMIUM: NOTIFICATION OF BOARD MEETING
CLSA Premium Expects Return to Profit in First Half
CLSA Premium (HKG:6877) expects to swing to a net profit of HK$5.2 million in the six months ended June 30 from a loss of HK$17.5 million a year earlier, a Monday filing said. The swing to profitabili
CLSA PREMIUM: POSITIVE PROFIT ALERT AND QUARTERLY UPDATE ON PROGRESS OF RESUMPTION
CLSA PREMIUM (06877): Suspension of the operation of margin trading business and continuing suspension of trading
According to the Zhitong Finance App, CLSA PREMIUM (06877) announced that since the Group initially began exploring the health products business in mid-2022, positive results have been achieved overall. In the first quarter of 2023, most of the Group's revenue and profit came from the health products business. Furthermore, the Board believes that the prospects for the Group's margin trading and precious metals trading business to gain new customers and improve performance are limited. Based on this, the Board of Directors believes that the resources and energy deployed in the margin trading business may be better used in the health products business, and therefore decided to suspend the operation of the margin trading business
CLSA PREMIUM (06877. HK) suspended this morning
Gelonghui, April 25 丨 CLSA PREMIUM (06877.HK) announced that trading of the company's shares will be suspended from 9:00 a.m. today (25/4/2023).
Hong Kong Bourse Upholds Suspension on CLSA Premium's Shares; Shares Tumble 12%
11:33 PM EDT, 04/13/2023 (MT Newswires) -- The listing committee of the Hong Kong Stock Exchange resolved to uphold its decision to suspend CLSA Premium's (HKG:6877) shares. The suspension comes after
CLSA PREMIUM (06877): The Listing Committee decided to suspend trading of the company's shares
According to the Zhitong Finance App, CLSA PREMIUM (06877) announced that on April 13, 2023, the company received a letter from the Listing Committee stating that after considering all the information (including written and oral) submitted by the company and the Listing Division, the Listing Committee decided to maintain the decision to suspend the company's share trading in accordance with section 6.01 (3) of the listing rules. The Listing Committee found that the company failed to maintain a sufficient level of operation and assets of sufficient value to support its operations in accordance with Rule 13.24 of the Listing Rules. The company is reviewing the listing committee's decision, as far as it is internal
No Data